Drug Pricing Developments Unfold: CMS Guidance, Constitutional Challenges, and Legislative Efforts in 2023
With the turning of the midpoint of 2023, the arena of drug pricing sees an influx of developments. The Centers for Medicare & Medicaid Services (CMS) finalized its guidance to prepare for unprecedented price negotiations, putting a highlight on the initial 10 drugs covered under the Innovation and Regulatory Affairs (IRA). Meanwhile, the constitutionality of…